SEC Filing Summary: Landec Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Landec Corporation on May 14, 2014, reporting events that occurred on May 8, 2014. The filing addresses corporate governance changes regarding the Board of Directors. Note: The request metadata referenced "LIFECORE BIOMEDICAL, INC.", but the source text explicitly identifies the registrant as Landec Corporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and contains no financial performance data.
Material Changes
- Board Expansion: The authorized number of directors on the Board of Directors was increased from nine (9) to ten (10).
- Director Election: Albert Bolles was elected as a Class 2 Director and appointed to the Nominating and Corporate Governance Committee.
- Conflict of Interest: Mr. Bolles has not had any direct or indirect material interest in transactions exceeding $120,000 since the beginning of the Company's last fiscal year.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the identity of the registrant (Landec Corporation) versus the metadata reference (Lifecore Biomedical).
- Confirm the new composition of the Board of Directors and the specific responsibilities of the Nominating and Corporate Governance Committee.
- Review subsequent filings for any financial impact related to the board expansion or new director appointments.